To announce that 2022Q2 consolidated financial
reports were submitted to the board of
directors.
Date of events
2022/08/05
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/05
2.Date of the audit committee approved:2022/08/05
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):472,019
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):249,438
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):18,987
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):25,825
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):20,552
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):11,727
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.25
11.Total assets end of the period (thousand NTD):1,792,265
12.Total liabilities end of the period
(thousand NTD):468,188
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,097,402
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bionet Corporation published this content on 05 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2022 08:10:01 UTC.
BIONET CORP. is a Taiwan-based company principally engaged in the storage and application of hematopoietic stem cells. The Companyâs main products include umbilical cord blood stem cells, mesenchymal stem cells, adult peripheral blood stem cells and others. The Company also provides precision medical application, prenatal testing and genetic testing services. The Company operates its businesses mainly in domestic market.